KYTHERA BIOPHARMACEUTICALS INC 4
4 · KYTHERA BIOPHARMACEUTICALS INC · Filed Feb 4, 2014
Insider Transaction Report
Form 4
Webster Jeffrey D
Senior VP, Operations
Transactions
- Sale
Common Stock
2014-02-03$45.90/sh−1,800$82,620→ 0 total - Exercise/Conversion
Stock Option (right to buy)
2014-02-03−4,000→ 50,761 totalExercise: $0.76Exp: 2017-03-13→ Common Stock (4,000 underlying) - Sale
Common Stock
2014-02-03$45.00/sh−2,200$98,998→ 1,800 total - Exercise/Conversion
Common Stock
2014-02-03$0.76/sh+4,000$3,040→ 4,000 total
Footnotes (4)
- [F1]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan which expires April 30, 2014.
- [F2]100% of the shares subject to the option are fully vested and exercisable.
- [F3]The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $44.57 to $45.50, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $45.515 to $46.33, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.